ACADIA Pharmaceuticals Inc. (LON:0A4W)

Market Cap	2.79B +14.4%
Revenue (ttm)	778.99M +12.7%
Net Income	194.30M +103.2%
EPS	1.15 +98.5%
Shares Out	n/a
PE Ratio	14.34
Forward PE	32.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101
Average Volume	1,809
Open	26.87
Previous Close	18.62
Day's Range	26.87 - 26.87
52-Week Range	16.31 - 26.87
Beta	n/a
RSI	85.57
Earnings Date	Feb 25, 2026

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 654
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4W

Financial Performance

Financial numbers in USD